Tinnen Quoted in Reorg About Termination Fees in Alexion Pharmaceuticals Proposed Acquisition of Portola Pharmaceuticals
12 May 2020
Reorg
Partner Clyde Tinnen was quoted in the Reorg article, “Past Alexion Guidance Bodes Well for Quick Review,” about Alexion’s planned acquisition of Portola in 2020. Although the deal is expected to withstand regulatory scrutiny, Portola would owe Alexion a termination fee in certain circumstances. “All things being equal, break up fees typically do provide a strong protective device for buyers to keep sellers in a deal,” Tinnen said.
(Subscription required)
People
Related News
20 September 2024
In the News
David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing
Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."
19 September 2024
In the News
Patrick Daugherty on UChicago's Desk Reference for Crypto, Web3 – 'This is very much for lawyers'
Foley & Lardner LLP partner Patrick Daugherty commented on the University of Chicago Law School's recently released open-access legal desk reference on crypto and Web3 matters in the Law.com article, "UChicago Law Professors Release Desk Reference Breaking Down Crypto, Web 3 for Attorneys."
18 September 2024
In the News
Eli Mazour Talks Patents on IPWatchdog Unleashed Podcast
Foley & Lardner of counsel Eli Mazour appeared on the IPWatchdog Unleashed podcast episode, "Problems, Solutions and the Case for Patents," to discuss patents and innovation, the Federal Circuit, the value of patents to clients, and patent strategy.